GlobalData on MSN5d
MSD’s CAPVAXIVE vaccine shows promise in pneumococcal disease trial
MSD’s CAPVAXIVE vaccine has demonstrated promising results from the STRIDE-8 Phase III trial, which showed positive immune ...
Merck posts positive trial data for Capvaxive pneumonia vaccine in at-risk adults
Merck (MRK) says it Capvaxive vaccine showed positive immune responses in a Phase 3 trial for adults at risk for pneumonia.
Business Wire7d
Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-8, a Phase 3 trial evaluating CAPVAXIVEâ„¢ (Pneumococcal ...
Investing7d
Merck's CAPVAXIVE shows promise in Phase 3 trial for pneumococcal disease
RAHWAY, N.J. - Merck & Co., Inc. (NYSE: MRK) has announced positive results from the STRIDE-8 Phase 3 trial of its pneumococcal 21-valent conjugate vaccine, CAPVAXIVE, presented at IDWeek 2024.
Pharmabiz6d
Merck’s STRIDE-8 phase 3 trial of Capvaxive demonstrates positive immune responses in adults with increased risk for pneumococcal disease
Merck’s STRIDE-8 phase 3 trial of Capvaxive demonstrates positive immune responses in adults with increased risk for pneumococcal disease: Rahway, New Jersey Thursday, October 1 ...
Investing7d
Merck's CAPVAXIVE shows promise in Phase 3 trial for pneumococcal disease
RAHWAY, N.J. - Merck & Co., Inc. (NYSE: MRK) has announced positive results from the STRIDE-8 Phase 3 trial of its pneumococcal 21-valent conjugate vaccine, CAPVAXIVE, presented at IDWeek 2024. The ...
Merck & Co. Inc. (MRK): Among the Best US Stocks for Foreign Investors Right Now
We recently compiled a list of the 8 Best US Stocks For Foreign Investors Right Now. In this article, we are going to take a ...